Impedimed Ltd Market Cap ($10.37 Million)
Market Cap & Net Worth: Impedimed Ltd (IPD)
Impedimed Ltd market cap. Impedimed Ltd (AU:IPD) has a market capitalization of $10.37 Million (AU$14.65 Million) as of November 4, 2026. Listed on the AU stock exchange, this Australia-based company holds position #26837 globally and #1235 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Impedimed Ltd's stock price AU$0.00 by its total outstanding shares 3662493691 (3.66 Billion). Also see Impedimed Ltd (IPD) cash flow conversion for how efficiently the company converts equity into cash flow.
Impedimed Ltd Market Cap History (2015–2026)
Impedimed Ltd market cap history from 2015 to 2026. Data shows change from $2.92 Billion to $10.37 Million (-38.61% CAGR). Check today's stock price for Impedimed Ltd for real-time trading data and today's change.
Impedimed Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Impedimed Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore IPD year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.71x
Impedimed Ltd's market cap is 0.71 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $2.51 Billion | $5.77 Million | -$27.57 Million | 435.28x | N/A |
| 2018 | $469.83 Million | $3.32 Million | -$27.25 Million | 141.60x | N/A |
| 2019 | $412.56 Million | $4.16 Million | -$24.00 Million | 99.27x | N/A |
| 2020 | $323.93 Million | $5.74 Million | -$21.38 Million | 56.42x | N/A |
| 2021 | $453.50 Million | $8.41 Million | -$20.71 Million | 53.93x | N/A |
| 2022 | $204.72 Million | $10.57 Million | -$19.87 Million | 19.38x | N/A |
| 2023 | $375.76 Million | $11.34 Million | -$20.52 Million | 33.12x | N/A |
| 2024 | $134.76 Million | $10.32 Million | -$19.79 Million | 13.06x | N/A |
| 2025 | $88.11 Million | $12.72 Million | -$23.24 Million | 6.92x | N/A |
| 2026 | $10.37 Million | $14.61 Million | -$24.91 Million | 0.71x | N/A |
Competitor Companies of IPD by Market Capitalization
Companies near Impedimed Ltd in the global market cap rankings as of November 4, 2026. Also see IPD total asset value for a full breakdown of the balance sheet.
Key companies related to Impedimed Ltd by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #110 globally with a market cap of $190.23 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #204 globally with a market cap of $119.12 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #226 globally with a market cap of $109.30 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #239 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #110 | Abbott Laboratories | NYSE:ABT | $190.23 Billion | $109.40 |
| #204 | Stryker Corporation | NYSE:SYK | $119.12 Billion | $310.55 |
| #226 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $98.88 |
| #239 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Market Capitalization of Impedimed Ltd (2015–2026)
Market capitalization of Impedimed Ltd from 2015 to today. Between 2015 and today, Impedimed Ltd's market cap moved from $2.92 Billion to $ 10.37 Million, with a yearly change of -38.61%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$10.37 Million | -88.24% |
| 2025 | AU$88.11 Million | -34.62% |
| 2024 | AU$134.76 Million | -64.14% |
| 2023 | AU$375.76 Million | +83.54% |
| 2022 | AU$204.72 Million | -54.86% |
| 2021 | AU$453.50 Million | +40.00% |
| 2020 | AU$323.93 Million | -21.48% |
| 2019 | AU$412.56 Million | -12.19% |
| 2018 | AU$469.83 Million | -81.28% |
| 2017 | AU$2.51 Billion | -1.46% |
| 2016 | AU$2.55 Billion | -12.71% |
| 2015 | AU$2.92 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Impedimed Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $10.37 Million USD |
| MoneyControl | $10.37 Million USD |
| MarketWatch | $10.37 Million USD |
| marketcap.company | $10.37 Million USD |
| Reuters | $10.37 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Impedimed Ltd
ImpediMed Limited, a medical technology company, engages in the development, manufacture, and sale of bioimpedance spectroscopy (BIS) systems and software services in Australia, Europe, North America, and internationally. The company offers SOZO Digital Health Platform which transforms fluid status and tissue composition into insights with a single scan; L-Dex Analysis for Lymphedema, designed fo… Read more